After decades of neglect, menopause and the impact it has on women’s life quality is becoming a major focus of pharmaceutical research. Hence the excitement this week about a new, potentially life-changing, drug.
Part of this is the growing recognition of what a huge market it is: the NHS estimates that 13 million women are currently peri- or menopausal in the UK, which is roughly a third of the female population. The most common symptom is hot flushes, which, in addition to fatigue, mood swings and muscle weakness, can seriously impact women’s wellbeing and productivity.
